Cancer has become a significant public health concern all over the world. This has created a need for outstanding publications of research and basic science on the oncology and cancer. This is needed not only by those working in cancer research but others who might be interested to know how to fight this illness. Oncotarget plays a significant role in cancer research due to its adherence to ethical guidelines. If you are looking for anything on cancer research, Oncotarget is the best journal to read.
Oncotarget a twice-weekly, open-access and peer-reviewed publication covers a multiplicity of topics on oncology and many other topics such as aging, microbiology, pathology, immunology, and chromosomes. The journal was established in 2010 and has published more than eight volumes and 324 issues since it’s inception. Visit Soundcloud to listen an audio podcast of Oncotarget.
Oncotarget’s mission is to make scientific knowledge and results widely available to eliminate challenges among multiple biomedical disciplines. Oncotarget promotes the application of research in the fight against cancer. It aims to promote a cancer-free society. The critical thing to note is that Oncotarget is mainly a publication by scientists for scientists, to help them as a resource in research.
Realizing after a brief spell of respite that their disease is drug-resistant and therefore incurable is the worst thing that can happen to most people diagnosed with cancer. This is devastating news for those suffering from papillary thyroid carcinoma (PTC) in particula as it is perhaps the most prevalent form of thyroid cancer.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/
Oncotarget provides valuable information about the latest research to help these patients. Ordinarily, the vemurafenib drug is used in the treatment of such patients. But recent tests have shown that the FDA-approved drug Palbociclib, are able to treat various forms of disease. Palbociclib also helps them to break down Vemurafenib drug resistance.
Researchers have also found that a combination of Vemurafenib and Palbociclib presents a potent option in the cure of PTC. They do this by working together to generate a stronger force that kills more cells than when the drug was working alone. The researchers also found that the combined therapy also targeted PTC cells while overcoming resistance. Visit Oncotarget’s profile page at facebook.com